Igor Matushansky, an adjunct professor of medical oncology at Columbia University and chief medical officer of Hookipa Biotech AG, has become a non-executive director of Crescendo Biologics Ltd, which is developing cancer therapeutics.
Dr Matushansky was previously an executive at Daiichi Sankyo Co Ltd and before that, global head for clinical and scientific development in Novartis’ gene and cell therapy unit. He was also an executive within Novartis’ oncology translational medicine unit. He received his MD and a PhD degree in molecular biology from the Albert Einstein College of Medicine, US.
Crescendo Biologics announced the appointment on 2 July 2018.
Evernow Publishing Ltd 2018.